Iontophoresis: A potential emergence of a transdermal drug delivery system

Scientia Pharmaceutica

Volumn 80, Issue 1, 2012, Pages 1-28

  Dhote, Vinod ^a   Bhatnagar, Punit ^a   Mishra, Pradyumna K ^b   Mahajan, Suresh C ^a   Mishra, Dinesh K ^a  

^a Mahakal Institute of Pharmaceutical Studies   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Drug delivery; Iontophoresis; Transdermal therapeutic system; Translational research

Indexed keywords

ARGININE; ATENOLOL; BUPRENORPHINE; CHLORHEXIDINE; DICLOFENAC; ELECTROLYTE; GENTAMICIN; ION; LEUPRORELIN; NALBUPHINE; OLIGONUCLEOTIDE; PIROXICAM; ROTIGOTINE; SALBUTAMOL; THIOCOLCHICOSIDE; TIMOLOL MALEATE; VASOPRESSIN;

ANATOMICAL VARIATION; BLOOD FLOW; BLOOD LEVEL; CELLS; CONCENTRATION (PARAMETERS); DENSITY; DENTISTRY; DERMATOLOGY; DIAGNOSTIC PROCEDURE; DIFFUSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; ELECTRODE; ELECTRONICS; ELECTROOSMOSIS; ELECTROPORATION; ENERGY RESOURCE; ENTROPY; HAIR FOLLICLE; HISTORY; HUMAN; HYDROPHILICITY; INTERCELLULAR SPACE; IONIC STRENGTH; IONIZATION; IONTOPHORESIS; MEDICAL RESEARCH; MEMBRANE TRANSPORT; MOLECULAR SIZE; MOLECULAR WEIGHT; MOLECULE; NONHUMAN; OPHTHALMOLOGY; OTORHINOLARYNGOLOGY; PH; PHYSICAL CHEMISTRY; POLARIZATION; PROCESS DEVELOPMENT; RESERVOIR; REVIEW; SKIN ALLERGY; SKIN PERMEABILITY; SWEAT GLAND; TRANSCELLULAR CELL MIGRATION; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT DURATION;

EID: 84857943462     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1108-20     Document Type: Review

References (91)

1. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2005; 2: 533-548. http://dx.doi.org/10.1517/17425247.2.3.533
2. Chien YW, Lelawongs P, Siddiqui O. Facilitated transdermal delivery of therapeutic peptides and proteins by iontophoretic delivery devices. J Control Release. 1990; 13: 263-278. http://dx.doi.org/10.1016/0168-3659(90)90017-N
3. Burnette RR, Ongpipattanakul B. Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci. 1987; 76: 765-773. http://dx.doi.org/10.1002/jps.2600761003
4. Harris MI. Diabetes in America, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Int J Pharm. 1995; 95:1468-1498.
5. Riviere JE, Heit MC. Electrically assisted transdermal drug delivery. Pharm Res. 1997; 14: 687-697. http://dx.doi.org/10.1023/A:1012129801406
6. Arunachalam S, Gunasekaran S. Diabetic research in India and China today: From literature-based mapping to health-care policy. Curr Sci. 2002; 82: 1086-1097.
7. Gangarosa L, James M. Modern iontophoresis for local drug delivery. Int J Pharm. 1995; 123: 159-171. http://dx.doi.org/10.1016/0378-5173(95)00047-M
8. Siddiqui O, Roberts M, Polock A. The effect of iontophoresis and vehicle pH on the in-vitro permeation of lignocaine through human stratum corneum. J Pharm Pharmacol. 1985; 37: 732-735. http://dx.doi.org/10.1111/j.2042-7158.1985.tb04954.x
9. Okave K, Yamaguchi H, Kawai Y. New Iontophoretic Transdermal Administration of Beta-Blocker Metoprolol. J Control Release. 1986; 4: 79-85. http://dx.doi.org/10.1016/0168-3659(86)90043-X
10. Chien YW. Transdermal route of peptide and protein drug delivery. Marcel Dekker Inc. New York. 1991; 667-690.
11. Prasad R, Koul V, Khar R. Transdermal iontophoretic delivery of methotrexate: physicochemical considerations. Trends Biomater Artif Organs. 2005; 18-25.
12. Scott RC. In-vitro absorption through damaged skin. In: Bronaugh RL, Maibach HI; eds. In Vitro Percutaneous Absorption, Principles, Fundamentals and Applications. Boca Radon: CRC Press.1991; 129-135.
13. Robert L. Transdermal drug delivery: past progress, current status, and future prospects. Adv Drug Deliv Rev. 2004; 56: 557-558. http://dx.doi.org/10.1016/j.addr.2003.10.021
14. Yogeshvar N, Naik A, Garrison J, Guy R. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004; 56: 619-658. http://dx.doi.org/10.1016/j.addr.2003.10.026
15. Hadgraft J, Guy RH. Transdermal Drug Delivery Development Issues and Research Initiatives. Marcel Dekker, Inc. New York. 1989; 35-96.
16. Guy RH, Marro D. Peptides and Proteins: Transdermal Absorption. In: James Swarbrick, ed. Encyclopedia of Pharmaceutical Technology. Third edition Marcel Dekker, Inc. New York. 2007; 2741-2755.
17. Singh I, Prasanthi S. Percutaneous penetration enhancement in transdermal drug delivery. Asian J Pharm. 2010; 92-101.
18. Sanderson J, Riel S. Iontophoretic delivery of nonpeptide drugs: Formulation optimization for maximum skin permeability. J Pharm Sci. 1989; 78: 361-364. http://dx.doi.org/10.1002/jps.2600780504
19. Bhatia K, Gao S, Freeman TP. Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin. J Pharm Sci. 1998; 96: 1011-1015. http://dx.doi.org/10.1021/js970023k
20. Bellantone N, Francoeur M, Rasadi B. Enhanced percutaneous absorption via iontophoresis I. Evaluation of an in vitro system and transport of model compounds. Int J Pharm. 1986; 30: 63-72. http://dx.doi.org/10.1016/0378-5173(86)90136-5
21. Schentz E, Fartach M. Microdialysis for the evaluation of penetration through the human skin barrier: A promising tool for future research. Eur J Pharm Sci. 1991; 12: 165-174. http://dx.doi.org/10.1016/S0928-0987(00)00155-X
22. Glass JM, Stephen RL, Jacobsen SC. The quality and distribution of radiolabelled dexamethasone delivered to tissues by iontophoresis. Int J Dermatol. 1979; 19: 519-515. http://dx.doi.org/10.1111/j.1365-4362.1980.tb00380.x
23. Stephen RL, Petelenz TZ, Jacobsen SC. Potential novel methods for insulin administration. Biomed Biochim Acta. 1984; 43: 553-558. http://www.ncbi.nlm.nih.gov/pubmed/6383361
24. Okabe K, Yamaguchi H, Kawai Y. New iontophoretic transdermal administration of the beta-blocker metoprolol. J Control Release. 1986; 4: 79-85. http://dx.doi.org/10.1016/0168-3659(86)90043-X
25. Wearley L, Liu JC, Chien YW. Iontophoresis- facilitated transdermal delivery of verapamil. J Control Release. 1989; 9: 231-242. http://dx.doi.org/10.1016/0168-3659(89)90091-6
26. Bhatia K, Singh J. Mechanism of transport enhancement of LHRH through Porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies. Pharm Res. 1998; 15: 1857-1862. http://dx.doi.org/10.1023/A:1011906022903
27. Marro D, Guy R. Characterization of the iontophoretic perselectivity properties of human and pig skin. J Control Release. 2000; 70: 213-217. http://dx.doi.org/10.1016/S0168-3659(00)00350-3
28. Figueroa M, Charro D, Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm. 2001; 212: 101-107. http://dx.doi.org/10.1016/S0378-5173(00)00599-8
29. Anderson CR, Morris RL, Boeh SD, Panus PC, Sembrowich WL. Effects of Iontophoresis Current Magnitude and Duration on Dexamethasone Deposition and Localized Drug Retention. Phys Ther. 2003; 83:161-170. http://www.ncbi.nlm.nih.gov/pubmed/12564951
30. Meidan VM, Khalili MA, Michniak BB. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int J Pharm. 2003; 264: 73-83. http://dx.doi.org/10.1016/S0378-5173(03)00390-9
31. Sebastiani P, Nicoli S, Santi P. Effect of lactic acid and iontophoresis on drug permeation across rabbit ear skin. Int J Pharm. 2005; 292: 119-126. http://dx.doi.org/10.1016/j.ijpharm.2004.11.038
32. Wang Y, Thakur R, Michniak B. Transdermal iontophoresis:combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm. 2005; 60: 179-191. http://dx.doi.org/10.1016/j.ejpb.2004.12.008
33. Mutalik S, Udapa N. Transdermal delivery of glibenclamide and glipizide: In-vitro permeation studies through mouse skin. Pharmazie. 2003; 12: 838-841. http://www.ncbi.nlm.nih.gov/pubmed/12561248
34. Mutalik S, Udapa N. Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal system of glibenclamide. J Pharm Sci. 2005; 8: 26-38. http://www.ncbi.nlm.nih.gov/pubmed/15946595
35. Mutalik S, Udupa N, Kumar S. Glipizide matrix transdermal systems for diabetes mellitus: Preparation, in-vitro and preclinical studies. Life Sci. 2006; 79: 1568-1577. http://dx.doi.org/10.1016/j.lfs.2006.05.002
36. Kolli C, Daniel L, Jayachandra R. Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate. Drug Devel Ind Pharm; in press. http://dx.doi.org/10.3109/03639045.2011.617753
37. Nair A, Vyas H, Shah J. Effect of permeation enhancers on the iontophoretic transport of metoprolol tartrate and the drug retention in skin. Drug Deliv. 2011; 8: 19-25. http://dx.doi.org/10.3109/10717544.2010.509361
38. Kinoshita M, Yamamoto R, Kominami K. In-vitro and in-vivo transdermal iontophoretic delivery of tramadol, a centrally acting analgesic. J Pharm Pharmacol. 2011; 63: 1437-1445. http://dx.doi.org/10.1111/j.2042-7158.2011.01355.x
39. Green P, Flalagan M. Iontophoretic drug delivery system. In: Walters KA, Hadgraft J; eds. Pharmaceutical Skin Penetration Enhancement, Marcel Dekker, New York. 1996; 100-124.
40. Green P, Flanagan M, Shroot B. Iontophoretic drug delivery. Marcel Dekker Inc New York. 1993; 311-333.
41. Chaturvedula A, Joshi DP, Anderson C, Morris RL, Sembrowich WL, Banga AK. In-vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. Int J Pharm. 2005; 297: 190-196. http://dx.doi.org/10.1016/j.ijpharm.2005.03.019
42. Masada T, Higuchi W, Behl C, Srinivasan V. Examination of iontophoretic transport of ionic drugs across skin: baseline studies with the four-electrode system. Int J Pharm. 1989; 49: 57-62. http://dx.doi.org/10.1016/0378-5173(89)90152-X
43. Charro D, Guy M. Iontophoresis of peptides. In: Electronically Controlled Drug Delivery. Berner B, Dinh SM; eds. CRC Press: Boca Raton. 1998; 129-157.
44. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin? Adv. Drug Deliv Rev. 1992; 9: 119-135. http://dx.doi.org/10.1016/0169-409X(92)90021-H
45. Singh J, Bahtia K. Topical iontophoretic drug delivery, Pathways, principles, factors and skin irritation. Med Res Rev. 1996; 16: 285-296. http://dx.doi.org/10.1002/(SICI)1098-1128(199605)16:3285::AID-MED43.0.CO;2-V.
46. Pikal M. Transport mechanisms in iontophoresis: A theoretical model for the effect of electro osmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res. 1990; 7: 118-126. http://dx.doi.org/10.1023/A:1015816532532
47. Pikal M, Shah S. Transport mechanisms in iontophoresis: Electro osmotic flow and transference number measurements for hairless mouse skin. Pharm Res. 1990; 7: 213-221. http://dx.doi.org/10.1023/A:1015857608850
48. Pikal M, Shah S. Transport mechanisms in iontophoresis: An experimental study of the contributions of electro osmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm Res. 1990; 7: 222-229. http://dx.doi.org/10.1023/A:1015809725688
49. Cevc G, Gebauer D, Stieber J, Schätzlein A, Blume G. Ultraflexible vesicles, transferosomes have an extremely low pore penetration resistance and transport therapeutic amount of insulin across the intact mammalian skin. Biochem Biophys Acta. 1995; 136: 201-215. http://dx.doi.org/10.1016/j.ijpharm.2005.03.019
50. Cullander C, Guy R. Sites of iontophoretic current flow into the skin: identification and characterization with the vibrating probe electrode. J Invest Dermatol. 1991; 97: 55-64. http://dx.doi.org/10.1111/1523-1747.ep12478060
51. Del T, Bhel C, Nash R. Iontophoretic transport of a homologues series of ionized and nonionized model compounds: Influence of Hydrophobicity and mechanistric interpretation. Pharm Res. 1989; 6: 85-90. http://dx.doi.org/10.1023/A:1015812005467
52. Dixit N, Baboota S, Ahuja A, Ali J. Iontophoresis-An Approach for Controlled Drug Delivery: A Review. Curr Drug Deliv. 2007; 4: 1-10. http://dx.doi.org/10.2174/156720107779314802
53. Bronaugh R, Maibach H. Percutaneous Absorption: Mechanisms - Methodology - Drug Delivery. Marcel Dekker, New York and Basel. 1989: 150-163.
54. Burnette R. Transdermal Drug Delivery. Marcel Dekker, New York. 1988; 45-63 and 202-246.
55. Banga AK, Chien YW. Iontophoretic delivery of drugs: Fundamentals, developments and biomedical applications. J Control Release.1988; 7: 1-24. http://dx.doi.org/10.1016/0168-3659(88)90075-2
56. Chien YW. Development of Transdermal drug delivery systems. Drug Dev Ind Pharm. 1987; 13: 589-651. http://dx.doi.org/10.3109/03639048709105212
57. Srinivasan V, Higuchi WI. A model for iontophoresis incorporating the effect of convective solvent flow. Int J Pharm. 1990; 60: 133-138. http://dx.doi.org/10.1016/0378-5173(90)90298-I
58. Tesselaar E, Sjoberg F. Transdermal iontophoresis as an in-vivo technique for studying microvascular physiology. Microvasc Res. 2011; 81(1): 88-96. http://dx.doi.org/10.1016/j.mvr.2010.11.002
59. Tierney M, Potts R, Tamada J. Glucose monitoring by reverse iontophoresis. Diabetes Metab Res Rev. 2002; 18: S49-S53. http://dx.doi.org/10.1002/dmrr.210
60. Mishra AN. Transdermal drug delivery. In: Jain NK, ed. Controlled and Novel Drug Delivery. Varghese Publication New Delhi. 1998: 100-129.
61. Jain NK. Controlled and Novel Drug Delivery. First ed. CBS publishers New Delhi. 2002; 202-240.
62. Patrizia S, Richard H. Reverse iontophoresis-parameters determining electro-osmotic flow. II. Electrode chamber formulation. J Control Release. 1996; 42: 29-36. http://dx.doi.org/10.1016/0168-3659(96)01345-4
63. Tierney MJ, Potts RO, Tamada JA. Glucose monitoring by reverse iontophoresis. Diabetes Metab Res Rev. 2002; 18: S49-S53. http://dx.doi.org/10.1002/dmrr.210
64. Huang JF, Sung KC, Hu OY, Wang JJ, Lin YH, Fang JY. The effects of electrically assisted methods on transdermal delivery of nalbuphine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels. Int J Pharm. 2005; 297: 162-271. http://dx.doi.org/10.1016/j.ijpharm.2005.03.015
65. Prausnitz MR, Bose VG, Langer R. Electroprotion of mamaliaon skin. A mechanism to enhance transdermal drug delivery. Proc Nat Acad Sci U S A. 1993; 90: 10504-10508. http://dx.doi.org/10.1073/pnas.90.22.10504
66. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. Int J Pharm. 1999; 179: 1-19. http://dx.doi.org/10.1016/S0378-5173(98)00360-3
67. Ritschel WA, Hussain AS. The principles of skin permeation. Meth Find Exptl Clin Pharmacol. 1988; 10: 39-56. http://www.ncbi.nlm.nih.gov/pubmed/3282132
68. Brain KR, Walters KA, Watkinson AC. Methods for studying percutaneous absorption. In: Walters KA, ed. Dermatological and transdermal formulations. Marcel Dekker Inc. New York. 2002: 241-247.
69. Singh P, Maibach HI. Iontophoresis in Drug Delivery: Basic Principles and Applications. Crit Rev Ther Drug Carrier Syst.1994; 11: 161-213. http://www.ncbi.nlm.nih.gov/pubmed/7600587
70. Riviere JE, Heit MC. Electrically assisted transdermal drug delivery. Pharm Res. 1997; 14: 687-697. http://dx.doi.org/10.1023/A:1012129801406
71. Mitragotri D, Blankschtein R, Langer H. Transdermal drug delivery using low- frequency sonophoresis. Pharm Res. 1996; 13: 411-420. http://dx.doi.org/10.1023/A:1016096626810
72. Mitragotri S, Blankschtein D, Langer R. Sonophoresis: Ultrasound mediated transdermal drug delivery. In: Swarbrick J, Boylan J; ed. Encylopedia of Pharmaceutical Technology. Marcel Dekker. 1995; 103-122. http://dx.doi.org/10.1023/A:1016096626810
73. Mitragotri S, Edwards D, Blankschtein D. A mechanistic study of ultrasonically enhanced transdermal drug delivery. J Pharm Sci. 1995; 84: 697-706. http://dx.doi.org/10.1002/jps.2600840607
74. Jacobsen J. Buccal iontophoretic delivery of atenolol·HCl employing a new in-vitro three-chamber permeation cell. J Control Release. 2001; 70: 83-95. http://dx.doi.org/10.1016/S0168-3659(00)00328-X
75. Bose S. Electrically-assisted transdermal delivery of buprenorphine. J Control Release. 2001; 73: 197-203. http://dx.doi.org/10.1016/S0168-3659(01)00298-X
76. Esther E, Binstock AJ. Iontophoresis: A non-invasive ocular drug delivery. J Control Release. 2006; 110: 479-489. http://dx.doi.org/10.1016/j.jconrel.2005.09.049
77. Kochhar C, Imanidis G. In-vitro transdermal iontophoretic delivery of leuprolide under constant current application. J Control Release. 2004; 98: 25-35. http://dx.doi.org/10.1016/j.jconrel.2004.04.008
78. Kadono M, Kubo K, Miyazaki H. Enhanced in-vitro percutaneous penetration of salicylate by ion pair formation with alkylamines. Biol Pharm Bullet. 1998; 21: 599-603. http://dx.doi.org/10.1248/bpb.21.599
79. Curdy C, Yogeshvar N, Guy R. Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion. J Control Release. 2001; 76: 73-79. http://dx.doi.org/10.1016/S0168-3659(01)00418-7
80. Williams C, Barry BW. Skin absorption enhancers. Crit Rev Ther Drug Carrier Syst. 1992; 9: 305-353. http://www.ncbi.nlm.nih.gov/pubmed/1458546
81. Panchagnula R, Pillai O, Nair VB. Transdermal iontophoresis. Curr Opin Chem Biol. 2000; 4: 468-473. http://dx.doi.org/10.1016/S1367-5931(00)00111-3
82. Artusi M, Nicoli S, Colombo P, Bettini R, Sacchi A, Santi P. Effect of chemical enhancers and iontophoresis on thiocolchicoside permeation across rabbit and human skin in vitro. J Pharm Sci. 2004; 93: 2431-2438. http://dx.doi.org/10.1002/jps.20152
83. Kanikannan JN, Singh J, Ramarao P. In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J Control Release. 2001; 71: 99-105. http://dx.doi.org/10.1016/S0168-3659(01)00208-5
84. Pillai O, Borkute S, Sivaprasad N. Transdermal iontophoresis of insulin: II. Physicochemical considerations: Int J Pharm. 2003; 254: 271-280. http://dx.doi.org/10.1016/S0378-5173(03)00034-6
85. Sakamoto T, Miyazaki Y, Aramaki E. Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin- 10 in NC/Nga mice. Genet Ther. 2004; 11: 317-324. http://dx.doi.org/10.1038/sj.gt.3302171
86. Shinde AJ, Shinde AL, Garala KC. Physical penetration enhancement by iontophoresis: a review. Int J Curr Pharm Res. 2010; 2: 1-9.
87. Gratieri T, Kalaria D, Kalia Y. Non-invasive iontophoretic delivery of peptides and proteins across the skin. Exp Opin Drug Deliv. 2011; 8: 645-663. http://dx.doi.org/10.1517/17425247.2011.566265
88. Mizejewski G. Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction. Exp Opin Invest Drugs. 2001; 10: 1063-1073. http://dx.doi.org/10.1517/13543784.10.6.1063
89. Valenta C, Siman U, Hadgraft J. The dermal delivery of lignocaine: influence of ion pairing. Int J Pharm. 2000; 197: 77-85. http://dx.doi.org/10.1016/S0378-5173(99)00453-6
90. Wearly LL, Liu JC, Chien YW. Iontophoresis facilitated transdermal delivery of verapamil I. In-vitro evaluation and mechanistic studies. J Control Release. 1989; 8: 237-250 http://dx.doi.org/10.1016/0168-3659(89)90045-X
91. Delgado-Charro MB. Iontophoretic drug delivery across the nail. Expert Opin Drug Deliv. 2012; 9: 91-103. http://dx.doi.org/10.1517/17425247.2012.642364